Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use
CA 2501940 A1 · Owner: Tolerrx, Inc. · Inventors: Rao, Patricia; Szymanska, Graznya
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is based, at least in part on the finding that certain , molecules are preferentially associated with effector T cells or regulatory T cells. Accordingly, immune responses by one or the other subset of cells can be preferentially modulated. The invention pertains e.g. to methods of , modulating (e.g. up- or down-modulating) the balance between the activation , of regulatory T cells and effector T cells leading to modulation of immune responses and to compositions useful in modulating those responses. The invention also pertains to methods useful in diagnosing treating, or , preventing conditions that would benefit from modulating effector T cell function relative …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 9, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 9, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 9, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.